NasdaqGS:PRAXBiotechs
Praxis Precision Medicines (PRAX) Is Up 34.4% After Dual Neurology Milestones - Has The Bull Case Changed?
Praxis Precision Medicines recently reported positive efficacy results from the registrational cohort of its EMBOLD trial of relutrigine in rare developmental and epileptic encephalopathies, and completed a pre-NDA FDA meeting for ulixacaltamide in essential tremor, with an NDA filing targeted for early 2026.
Together, these programs highlight Praxis’s effort to build a focused neurology franchise that spans ultra-rare pediatric epilepsies and a large, underserved essential tremor...